Table 2.
Patient and disease characteristics at baseline: efficacy population (N = 285)
| Total, N = 285 | |
|---|---|
| Patients’ characteristics | |
| Age (years), mean ± SD | 56.3 ± 12.5 |
| Women, no. (%) | 213 (74.7) |
| BMI (kg/m2), mean ± SD | 26.3 ± 5.4 (n = 269) |
| Past or concomitant diseases | |
| Patients with at least one past or concomitant disease, no. (%) | 205 (71.9) |
| RA history | |
| RA duration (years), mean ± SD | 9.4 ± 9.0 |
| Positive RF or ACPA, no. (%) | 236 (83.4) (n = 283) |
| Erosive RA*, no. (%) | 172 (60.8) (n = 283) |
| Structural damage**, no. (%) | 87 (32.7) (n = 266) |
| Previous RA treatment | |
| csDMARDs | |
| At least one prior csDMARD, no. (%) | 269 (94.4) |
| Number of previous csDMARDs, mean ± SD | 1.8 ± 1.0 (n = 269) |
| Previous MTX, no. (%) | 259 (90.9) |
| Started 2 years prior to inclusion, no. (%) | 83 (33.5) (n = 248) |
| At least one other prior csDMARD, no. (%) | 142 (49.8) |
| bDMARDs | |
| At least one prior bDMARD, no. (%) | 179 (62.8) |
| Number of previous bDMARDs, mean ± SD | 1.8 ± 0.9 (n = 179) |
| Oral glucocorticoids | |
| At least one prior oral glucocorticoid, no. (%) | 215 (75.7) (n = 284) |
| Delay between last dose and inclusion (years), mean ± SD | 1.4 ± 3.2 (n = 208) |
| Other treatments for RA# | |
| At least one prior other treatment, no. (%) | 194 (68.6) (n = 283) |
| Concomitant RA treatments at first TCZ-SC injection, no. (%) | (n = 282) |
| MTX | 134 (47.5) |
| At least one other csDMARD | 28 (9.9) |
| Oral glucocorticoid | 138 (48.9) |
| RA characteristics at inclusion, mean ± SD | |
| DAS28-ESR | 4.77 ± 1.21 (n = 252) |
| SDAI | 25.43 ± 11.42 (n = 246) |
| CDAI | 23.90 ± 10.76 (n = 256) |
| HAQ-DI standard score | 1.32 ± 0.69 (n = 261) |
| Global assessment of disease activity (physicians’ VAS, mm) | 55.2 ± 19.6 (n = 257) |
| Global assessment of disease activity (patients’ VAS, mm) | 58.4 ± 22.3 (n = 279) |
| EQ-5D-3L—index score | 0.38 ± 0.33 (n = 257) |
ACPA anti-citrullinated protein antibody, BMI body mass index, CDAI Clinical Disease Activity Index, cs/bDMARD conventional synthetic/biologic disease-modifying antirheumatic drug, DAS28-ESR Disease Activity Score 28 joints-Erythrocyte Sedimentation Rate, EQ-5D-3L EuroQol Group-5 Dimensions 3 Levels, HAQ-DI Health Assessment Questionnaire-Disability Index, MTX methotrexate, RA rheumatoid arthritis, RF rheumatoid factor, SD standard deviation, SDAI Simplified Disease Activity Index, TCZ-SC subcutaneously administered tocilizumab, VAS visual analogue scale
*Worsening at X-ray during RA at any time
**Worsening at X-ray over the past 2 years
#Nonsteroidal anti-inflammatory drugs [152/283 (53.3%)] or infiltration with corticosteroids [106/283 (37.2%)] or intramuscular corticosteroids [3/283 (1.1%)] or intravenous bolus corticosteroids [33/283 (11.6%)]